Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
GC Medical Science corp.

Download Mobile App




Ablation for AF Reduces Mortality and Stroke

By HospiMedica International staff writers
Posted on 09 Jul 2018
A new study suggests that catheter-based ablation lowers the risk of mortality, ischemic stroke, and hemorrhagic stroke in patients with atrial fibrillation (AF).

Researchers at the University of California Davis (UCD; USA) conducted a study to compare stroke and mortality in 4,169 AF patients who underwent ablation and 4,169 matched controls, selected by years of AF diagnosis, age, sex, and being alive the same number of days from the initial AF encounter to the ablation date. Those with valve disease, open maze, other arrhythmias, or implantable devices were excluded. Mortality and ischemic or hemorrhagic stroke were assessed, with adjustment for demographics, prior admissions with AF before the ablation, calendar year, and presence of chronic comorbidities.

The results revealed that while outcomes within 30 days of hospitalization were similar for both groups, long-term benefits of ablation became apparent after 3.6 years or more of follow-up. At that time, 84 patients died in the ablation group, compared to 189 in the control group; 55 patients in the ablation group suffered ischemic stroke, versus 86 in the control group; and 17 patients in the ablation group had hemorrhagic strokes, compared to 53 in the control group. The study was published on June 8, 2018, in Circulation: Arrhythmia and Electrophysiology.

“Ablation is currently only recommended when AF medications don't work, or aren't well tolerated. Less than two percent of patients undergo ablation early in the course of AF, when the procedure can be most beneficial,” said lead author professor of cardiovascular medicine Uma Srivatsa, MD. “Our data supports wider utilization of ablation along with improving the awareness of its benefits. Ablation may be considered as a primary treatment for everyone with the condition.”

Cardiac catheter ablation procedures are used to treat a variety of cardiac arrhythmias, especially supraventricular tachyarrhythmias such as AF, atrial flutter, and atrial tachycardia. The procedures involve advancing a catheter into the heart and selectively ablating certain areas of tissue in order to prevent the spread of electrical signals that give rise to the arrhythmia. The procedure is low-risk and usually takes 2-4 hours. It is most often performed in an electrophysiology or a cardiac catheterization lab. It is successful in about 90% of the people who have it.

Related Links:
University of California Davis


Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
Gold Member
STI Test
Vivalytic Sexually Transmitted Infection (STI) Array
New
CPAP Machine
EcoStar Auto
New
Prostate Cancer MRI Analysis Tool
DynaCAD Urology
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get complete access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Surgical Techniques

view channel
Image: The Trilogy Valve with locator technology is the only TAVI system approved for aortic regurgitation (Photo courtesy of JenaValve)

New Transcatheter Valve Found Safe and Effective for Treating Aortic Regurgitation

Aortic regurgitation is a condition in which the aortic valve does not close properly, allowing blood to flow backward into the left ventricle. This results in decreased blood flow from the heart to the... Read more

Patient Care

view channel
Image: The portable biosensor platform uses printed electrochemical sensors for the rapid, selective detection of Staphylococcus aureus (Photo courtesy of AIMPLAS)

Portable Biosensor Platform to Reduce Hospital-Acquired Infections

Approximately 4 million patients in the European Union acquire healthcare-associated infections (HAIs) or nosocomial infections each year, with around 37,000 deaths directly resulting from these infections,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.